Linagliptin attenuates kidney cancer in rats via AMPK activation and suppression of YAP/TAZ/HIF-1α signaling
Rattachement africain : sa, Égypte, de, it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study investigated the renoprotective action of linagliptin compared to doxorubicin against thioacetamide (TAA) and diethyl nitrosamine (DEN)-induced renocarcinogenesis in a rat model. Male Wistar rats were divided into control, renocarcinogenesis (RCC), doxorubicin group (7.5 mg/kg, i.p., once weekly), and linagliptin (Lina) groups (3 and 6 mg/kg/day, p.o.). The experiment included renal function parameters, oxidative stress markers, and predominant molecular pathways involved in renal pathogenesis. The RCC model significantly impaired renal function, as reflected in elevated serum levels of urea and creatinine. It also resulted in elevated oxidative stress, as reflected in increased malondialdehyde (MDA) content and decreased glutathione and superoxide dismutase (GSH and SOD) activities. The model disrupted several molecular pathways, including the AMP-activated protein kinase (AMPK) pathway, and enhanced oncogenic and inflammatory markers such as Yes-associated protein/ Transcriptional coactivator with PDZ-binding motif/ Hypoxia-inducible factor 1-alpha (YAP/TAZ/ HIF-1α), nuclear factor erythroid 2-related factor 2/ Sirtuin 1(Nrf2/SIRT1), and signal transducer and activator of transcription 3 (STAT3). Treatment with linagliptin, particularly the high dose (6 mg/kg/day), was found to be superior to doxorubicin treatment in terms of correction of renal function and markers of oxidative stress. Linagliptin effectively regulated the AMPK pathway, reduced markers of inflammation, restored the expression of genes with key roles in renal protection, reduced proliferating Cell Nuclear Antigen (PCNA), and elevated Caspase-3. The high dose of linagliptin exhibited superior results in most of the parameters, which approached control levels more than those with the lower dose and doxorubicin. These findings demonstrate that linagliptin, especially at 6 mg/kg/day, exhibits significant renoprotective activities through multifarious mechanisms involving antioxidant action and regulation of key molecular pathways. The present study presents evidence for the potential therapeutic application of linagliptin in renal manifestations of renocarcinogenesis.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Linagliptin attenuates kidney cancer in rats via AMPK activation and suppression of YAP/TAZ/HIF-1α signaling
- Date Crossref
- 01/02/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Taibah University Health and Life Research Center pays non établi dans la noticeUniversité ou école supérieure
-
National Research Centre Égypte (code pays fourni par la source)Structure de recherche
-
Cairo University Cairo University, Égypte (code pays fourni par la source)Université ou école supérieure
-
Leibniz University Hannover Department of Molecular Food Chemistry and Food Development pays non établi dans la noticeUniversité ou école supérieure
-
University of Bologna Department for Life Quality Studies pays non établi dans la noticeUniversité ou école supérieure
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
College of Pharmacy Department of Pharmacology and Toxicology pays non établi dans la noticeUniversité ou école supérieure
-
Medical Research and Clinical Studies Institute Department of Pharmacology Giza, Égypte (pays nommé en fin d’affiliation)Structure de recherche
-
Biotechnology Research Institute Biochemistry Department Giza, Égypte (pays nommé en fin d’affiliation)Structure de recherche
-
Faculty of Veterinary Medicine Department of Pharmacology Cairo University, Égypte (pays nommé en fin d’affiliation)Université ou école supérieure
-
Indiana University School of Medicine Stark Neurosciences Research Institute pays non établi dans la noticeUniversité ou école supérieure
Health and Life Research Center — Taibah University, National Research Centre (Égypte) et Cairo University (Cairo University, Égypte), avec 8 autres affiliations. Pays d’affiliation : Égypte.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.